Maryland-based In Vitro Technologies (IVT) supplies products and services to improve the drug discovery and development process. The company’s product portfolio includes proprietary ADME-Tox products, including fresh and cyropreserved cells and enzymes. In acquiring the company, Celsis will be able to add such products and services for the in vitro ADME toxicology market to its portfolio, thus expanding its offerings.
An estimated 50% of drug candidates fail in clinical trials due to unanticipated pharmacokinetic and toxicology issues. According to IVT, its broad range of tools can help to avoid this by aiding with the selection of optimum candidates for the clinical trial stage.
The integration of IVT into Celsis is expected to create significant value for customers of both companies through the combination of complementary products, services and knowledge.
“We could not have hoped for a better strategic partner than Celsis,” said Dr Paul Silber, founder of IVT. “The synergy created by joining forces will create a strong team with great potential for future growth.”